Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE